Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Revvity Inc (RVTY) Price & Performance

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Revvity Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.71 (market cap $7.77B), while Revvity Inc trades at $154.16 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.2× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Revvity Inc pays a 0.18% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Revvity Inc for 12 Days on average.

PDBCRVTY
Market Cap
$7.77B$16.98B
Volume
6,100,3031,456,900
52-Week High
$20.10$157.36
52-Week Low
$13.16$82.26
Typical Hold Time
56 Days12 Days
Sector
—Health
Enterprise Value
—$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.66, up 1.29% with strong bullish momentum from moving averages. The ETF has delivered exceptional performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows significant position increases despite a 215% surge in short interest in September.

The outlook remains positive given strong commodity trends and defensive positioning benefits, though elevated short interest and RSI levels near overbought territory suggest potential near-term volatility. Commodity exposure provides inflation hedging advantages but remains sensitive to geopolitical developments and global economic conditions.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PDBC
1% Buy99% Sell
Avg holding period · 56 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.

Read more on PDBC →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →